Expanded Funding Program Strengthens Enterprise Innovation’s Ability to Nurture Promising Early-Stage Research
May 21, 2025
To support the continued diversification of Weill Cornell Medicine’s technology portfolio, Enterprise Innovation has created an overarching gap funding superstructure to advance innovation and commercialization opportunities.Making a Real-World Impact with Tangible Research Materials Commercialization
May 16, 2025
Tangible materials developed by Weill Cornell Medicine investigators are valuable assets to both the research community and biomedical industry. By commercializing such materials, investigators can propel translational science as well as create revenue for their labs. Dr. Lukas Dow, a professor of biochemistry in medicine who has a decade of experience in commercializing tangible materials, shared his insights with Enterprise Innovation.
AI Tool Accurately Sorts Cancer Patients by their Likely Outcomes
May 12, 2025
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine. The new approach has the potential to enable better patient selection in clinical trials and better treatment selection for individual patients.
The Power of Partnership in Innovation
April 14, 2025
Nearly 200 scientists, investors and industry representatives attended Weill Cornell Medicine’s 2025 Biomedical Innovation Conference (“BioInnovate”) April 1, sharing their startup journeys and experiences nurturing biomedical advances into health care products and companies.
New Strategy May Enable Cancer Monitoring from Blood Tests Alone
April 11, 2025
A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators. The method, based on whole-genome sequencing of DNA, also represents an important step toward the goal of routine blood test-based screening for early cancer detection.
Wound Healing Innovation Obtains FDA 510(K) Clearance to Help Improve Patient Outcomes
March 12, 2025
Dr. Jason Spector, founder of Fesarius Therapeutics, and the company's President and CEO Tom Roueche spoke to Enterprise Innovation about their medical device, the process and significance of its obtaining FDA 510(k) clearance.
FLIpping the Switch: Boosting Stem Cell Numbers for Therapies
March 10, 2025
A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators. The discovery could lead to more effective bone marrow transplants and gene therapies.
Mapping of Specialized Blood Vessel Cells May Lead to Diabetes Treatments
February 6, 2025
The distinct population of endothelial cells that line blood vessels in the insulin-producing “islets” of the human pancreas have been notoriously difficult to study, but Weill Cornell Medicine investigators have now succeeded in comprehensively detailing the unique characteristics of these cells. The resulting atlas advances basic research on the biology of the pancreas and could lead to new treatment strategies for diabetes and other pancreatic diseases.
Innovators Encourage Scientists and Physicians to Dive into Technology Commercialization
January 9, 2025
In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.